MarketScreener Editorial Features Genmab A/S

Stocks

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-12 EDT			5-day change	1st Jan Change
1,619.00 ^DKK	+0.15%		+2.24%	-20.13%

06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

	Weekly Earnings Calendar: Palantir, AMD, AXA and Engie in the Spotlight	May 04, 2026 at 05:21 am
	Weekly Earnings Calendar: Palantir, AMD, AXA and Engie in the Spotlight	May 04, 2026 at 05:18 am
	Genmab: From now on, courage to the most patient	April 01, 2025 at 10:57 am
	New entries in MarketScreener's Europe portfolio	August 05, 2024 at 04:47 am
	New entries in MarketScreener's Europe portfolio	December 08, 2023 at 06:02 am
	Analyst recommendations: Charter Communications, Chevron, Match Group, Shopify, Spotify...	May 02, 2022 at 08:02 am